BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, Beaugrand M, Charnaux N. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 2008; 14(5): 713-719 [PMID: 18205260 DOI: 10.3748/wjg.14.713] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Huang F, Geng XP. Chemokines and hepatocellular carcinoma. World J Gastroenterol 2010; 16(15): 1832-1836 [PMID: 20397259 DOI: 10.3748/wjg.v16.i15.1832] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
2 Smith DA, Harrison A, Morgan P. Multiple Factors Govern the Association between Pharmacology and Toxicity in a Class of Drugs: Toward a Unification of Class Effect Terminology. Chem Res Toxicol 2011;24:463-74. [DOI: 10.1021/tx100408v] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Liu T, Zhai J, Wang H, Wang X, Zou L, Fan W, Ye D. Meta-analysis of MCP-1 promoter −2518 A/G polymorphism and SLE susceptibility. Mol Biol Rep 2012;39:8475-82. [DOI: 10.1007/s11033-012-1701-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ma H, Shu Y, Pan S, Chen J, Dai J, Jin G, Hu Z, Shen H. Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer 2011;74:164-9. [DOI: 10.1016/j.lungcan.2011.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
5 Wang Y, Zhang XA, Yang X, Wu ZH, Feng ZC. A MCP-1 promoter polymorphism at G-2518A is associated with spontaneous preterm birth. Mol Genet Genomics 2015;290:289-96. [PMID: 25234163 DOI: 10.1007/s00438-014-0921-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113:756-762. [PMID: 26270232 DOI: 10.1038/bjc.2015.227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
7 Santos EU, Lima GD, Oliveira Mde L, Heráclio Sde A, Silva HD, Crovella S, Maia Mde M, Souza PR. CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study. Mem Inst Oswaldo Cruz 2016;111:174-80. [PMID: 26982176 DOI: 10.1590/0074-02760150367] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Stewart TJ, Smyth MJ. Chemokine–chemokine receptors in cancer immunotherapy. Immunotherapy 2009;1:109-27. [DOI: 10.2217/1750743x.1.1.109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
9 Rebbani K, Ezzikouri S, Marchio A, Ababou M, Kitab B, Dejean A, Kandil M, Pineau P, Benjelloun S. Common polymorphic effectors of immunity against hepatitis B and C modulate susceptibility to infection and spontaneous clearance in a Moroccan population. Infection, Genetics and Evolution 2014;26:1-7. [DOI: 10.1016/j.meegid.2014.04.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
10 Khorramdelazad H, Hakimizadeh E, Hassanshahi G, Rezayati M, Sendi H, Arababadi MK. CCR5 Δ 32 mutation is not prevalent in Iranians with chronic HBV infection. J Med Virol 2013;85:964-8. [DOI: 10.1002/jmv.23510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, Ma HJ, Chou MC, Tsai HT, Yang SF. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med 2009;47:412-8. [PMID: 19327121 DOI: 10.1515/CCLM.2009.092] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
12 Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol. 2012;57:663-674. [PMID: 22609306 DOI: 10.1016/j.jhep.2012.02.035] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 10.3] [Reference Citation Analysis]
13 Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol 2015; 7(17): 2080-2090 [PMID: 26301050 DOI: 10.4254/wjh.v7.i17.2080] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
14 Kruszyna Ł, Lianeri M, Rubis B, Knuła H, Rybczyńska M, Grodecka-gazdecka S, Jagodziński PP. CCL2 −2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep 2011;38:1263-7. [DOI: 10.1007/s11033-010-0225-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
15 Khorramdelazad H, Mortazavi Y, Momeni M, Arababadi MK, Khandany BK, Moogooei M, Hassanshahi G. Lack of Correlation Between the CCR5-Δ32 Mutation and Acute Myeloid Leukemia in Iranian Patients. Indian J Hematol Blood Transfus 2015;31:29-31. [PMID: 25548441 DOI: 10.1007/s12288-014-0408-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
16 Grzegorzewska AE, Świderska MK, Mostowska A, Jagodziński PP. Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. Biomed Res Int 2017;2017:3713025. [PMID: 29226133 DOI: 10.1155/2017/3713025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S, Singh R. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 32260550 DOI: 10.3390/cancers12040883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J, Zhong CP. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol 2015; 7(10): 1390-1402 [PMID: 26052384 DOI: 10.4254/wjh.v7.i10.1390] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
19 Yeh CB, Tsai HT, Chen YC, Kuo WH, Chen TY, Hsieh YH, Chou MC, Yang SF. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol. 2010;102:264-270. [PMID: 20740585 DOI: 10.1002/jso.21623] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
20 Dagouassat M, Suffee N, Hlawaty H, Haddad O, Charni F, Laguillier C, Vassy R, Martin L, Schischmanoff PO, Gattegno L, Oudar O, Sutton A, Charnaux N. Monocyte chemoattractant protein-1 (MCP-1)/CCL2 secreted by hepatic myofibroblasts promotes migration and invasion of human hepatoma cells. Int J Cancer 2010;126:1095-108. [PMID: 19642141 DOI: 10.1002/ijc.24800] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 0.9] [Reference Citation Analysis]
21 Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of Polymorphisms in MCP-1, CCR2, and CCR5 Genes with the Risk and Clinicopathological Characteristics of Prostate Cancer. DNA and Cell Biology 2012;31:1418-24. [DOI: 10.1089/dna.2012.1716] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
22 Ghorban K, Dadmanesh M, Hassanshahi G, Momeni M, Zare-Bidaki M, Arababadi MK, Kennedy D. Is the CCR5 Δ 32 mutation associated with immune system-related diseases? Inflammation. 2013;36:633-642. [PMID: 23250822 DOI: 10.1007/s10753-012-9585-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
23 Danilenko NG, Siniauskaya MG, Lukashyk SP, Karpov IA, Davydenko OG. “Double Punch”: Hepatitis C in Patients with Genetic Defects of Iron Metabolism. Cytol Genet 2019;53:407-17. [DOI: 10.3103/s0095452719050062] [Reference Citation Analysis]
24 Chaudhry S, Emond J, Griesemer A. Immune Cell Trafficking to the Liver. Transplantation 2019;103:1323-37. [PMID: 30817405 DOI: 10.1097/TP.0000000000002690] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
25 Wang XZ, Huang XY, Yao JG, Wang C, Xia Q, Long XD. Genetic polymorphisms in ataxin-3 and liver cirrhosis risk related to aflatoxin B1. Oncotarget 2018;9:27321-32. [PMID: 29937988 DOI: 10.18632/oncotarget.24535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Mohit M, Hajghani M, Shamsizadeh A. Peripheral Blood CD8 + T Cells CCR5 Expression and Its Δ32 Mutation in Iranian Patients with Occult Hepatitis B Infections. Lab Med 2010;41:226-30. [DOI: 10.1309/lmvukwrox0ebqr01] [Cited by in Crossref: 11] [Article Influence: 0.9] [Reference Citation Analysis]
27 Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Mohit M, Hajghani M, Ahmadabadi BN, Kennedy D. Evaluation of CCR5 Expression on NK Cells in Iranian Patients With Occult Hepatitis B Infection. Lab Med 2010;41:735-8. [DOI: 10.1309/lmauisl84q4srsbt] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]